Conversely, in a cohort of MMRd CRC, JAK1 loss-of-function mutations were positively associated with better patient outcome (258) and EC MMRd patients with JAK1 mutations benefited from anti-PD-1 treatment (156). Here, JAK1 is linked to colorectal carcinoma.